Condition: Leukemia, Acute Lymphoblastic · Lymphoma, Non-Hodgkin · Sponsor: University of Sao Paulo
The goal of this prospective, multicentric, single-arm, phase I/II clinical trial is to evaluate the safety and efficacy of a novel CD19-directed CAR-T cell locally produced in an academic institution in Brazil in patients with refractory or relapsed acute lymphoblastic leukemia or non-Hodgkin lymphoma. Participants will receive a single intravenous infusion of an autologous academic anti-CD19 CAR-T cell and will be followed for 5 years.
This description comes directly from the study's public registry record.
Diego V Cle, MD, PhD, MBA · +551621019300 · terapia@hemocentro.fmrp.usp.br
Always discuss trial participation with your own doctor first.
| Hospital de Clínicas da UNICAMP | Campinas, São Paulo, Brazil | Recruiting |
| Ribeirao Preto School of Medicine, University of Sao Paulo | Ribeirão Preto, São Paulo, Brazil | Recruiting |
| Hospital Sírio-Libanês | São Paulo, São Paulo, Brazil | Recruiting |
| Hospital das Clinicas de São Paulo | São Paulo, São Paulo, Brazil | Recruiting |
| A Beneficência Portuguesa de São Paulo | São Paulo, São Paulo, Brazil | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06101381